What Will Happen to NANOBAC PHARMACEUTLS (OTCMKTS:NNBP) Next? The Stock Has Decline in Shorts

July 18, 2017 - By Marie Mckinney

The stock of NANOBAC PHARMACEUTLS (OTCMKTS:NNBP) registered a decrease of 40% in short interest. NNBP’s total short interest was 23,400 shares in July as published by FINRA. Its down 40% from 39,000 shares, reported previously. With 122,800 shares average volume, it will take short sellers 0 days to cover their NNBP’s short positions.

It closed at $0.0007 lastly. It is down 0.00% since July 18, 2016 and is . It has underperformed by 16.70% the S&P500.

Nanobac Pharmaceuticals, Incorporated is a research-based, bio-lifescience company. The company has market cap of $135,839. The Firm is primarily engaged in the discovery and development of services and products to improve people’s health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as nanobacteria. It currently has negative earnings. The Company’s research is directed toward establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.

More important recent Nanobac Pharmaceuticals, Inc. (OTCMKTS:NNBP) news were published by: Reuters.com which released: “National Diagnostics, Inc. Completes Merger With American Enterprise.com, Corp.” on February 15, 2000, also Reuters.com published article titled: “Nanobac Life Sciences, Inc. And Eureka Genomics Sign Merger Agreement”, Bizjournals.com published: “Trump criticism leads to falling stock prices at these Tampa employers” on January 12, 2017. More interesting news about Nanobac Pharmaceuticals, Inc. (OTCMKTS:NNBP) was released by: Nature.com and their article: “Nanobacteria theory takes a hit” with publication date: April 18, 2008.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: